Oxysterol-EBI2 signaling in immune regulation and viral infection

Viktorija Daugvilaite*1, Kristine Niss Arfelt*1, Tau Benned-Jensen2, Andreas W. Sailer3 and Mette M. Rosenkilde1

1 Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
2 The Ion channel Group, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
3 Developmental & Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland

The seven transmembrane G protein-coupled receptor Epstein-Barr virus (EBV) induced gene 2 (EBI2; also known as GPR183) was identified in 1993 on the basis of its substantial upregulation in EBV-infected cells. It is primarily expressed in lymphoid cells; most abundantly in B cells. EBI2 is central for the positioning of B cells within the lymphoid organs, a process that is regulated in part by a chemotactic gradient formed by the endogenous lipid agonists, and in part by a fine-tuned regulation of EBI2 cell surface expression. The most potent endogenous EBI2 agonist is 7α,25-dihydroxycholesterol (7α,25-OHC), yet many structurally related oxysterols can bind to an EBI2 pocket that is defined by the upper parts of the transmembrane helices and extracellular receptor regions. EBI2 signals via Gi, as well as via G protein-independent pathways like β-arrestin recruitment. The concerted action of these pathways leads to cell migration. By genetically interfering with its up- and downregulation, EBI2 was also recently shown to induce cell proliferation, an action that could be inhibited by small molecule antagonists. Here, we focus on the oxysterol–EBI2 axis in immune control, including its role in the EBV life cycle. We also summarize the structural and functional properties of EBI2 interaction with oxysterol agonists and small molecule antagonists and discuss EBI2 as therapeutic target for diseases of the immune system.

Keywords: 7TM receptor • Epstein-Barr virus-induced gene 2 • GPCR • GPR183 • Oxysterols

See accompanying review by Traversari et al.

Introduction

Epstein-Barr virus-induced molecule 2 (EBI2; also known as GPR183) couples to Gai [1] and belongs to the rhodopsin-like subfamily of class A transmembrane spanning (7TM) G protein-coupled receptors, which constitute the largest protein subfamily in the human genome with 170 members. This subclass contains several important drug targets, as approximately 35% of all currently marketed drugs bind to class A receptors [2]. These receptors control many aspects of normal physiology from taste...
and visual perception, function of central and peripheral nervous system, gastrointestinal and appetite control, broncho-alveolar and cardiovascular regulation to immune system homeostasis and surveillance.

EBI2 was identified in 1993 as the most upregulated gene in Epstein-Barr virus (EBV) infected lymphocytes [3], hence the name Epstein-Barr Virus induced gene 2 (EBI2). This upregulation was confirmed in two subsequent studies one decade after the initial discovery [4, 5]. EBI2 signaling through Gαi was described for the first time in 2006 [1], and multiple G protein-dependent and -independent pathways have been described ever since [6–8] (Fig. 2A), including the latest described activation of MAP-kinases in 2013 [9]. In 2011, the first EBI2-specific small molecule antagonists were presented [8]. These molecules were shown to inhibit Gαi signaling, as well as EBI2-induced cell migration and proliferation [8], and have been suggested to bind in the main binding crevice defined by the transmembrane helices in EBI2 [9]. A major breakthrough came in 2009, when the biological role of EBI2 in immune system surveillance was uncovered: EBI2 was described to mediate B-cell migration within secondary lymphoid organs [10, 11]. It took 2 years until endogenous EBI2 agonists that control B-cell migration were identified. Intriguingly, these agonists did not belong to the protein-based cytokines, but to a subfamily of hydroxylated cholesterol metabolites [6, 7]. All in all, within less than 10 years, the status of EBI2 has shifted from being an orphan receptor with unknown biological roles to being characterized as a receptor for endogenous oxysterols. Importantly, this discovery also greatly enhanced our understanding of the mechanisms through which oxysterols act in the immune system. Furthermore, with the identification of the first EBI2 antagonists [8, 9], and an increasing knowledge of the mechanisms through which EBI2 controls the immune system [6, 7, 10–12] — among others, through its fine-tuned interplay with chemokine receptors such as CXCR5 and CCR7 [13, 14] — we are getting closer to a putative drug target validation of EBI2.

In the present review, we summarize current knowledge of the oxysterol–EBI2 axis in immune control and the immune system-dependent role of EBI2 during EBV infection. In addition, we overview the signaling properties of EBI2 as well as the structural and functional aspects of its interaction with oxysterol agonists and small molecule antagonists. Ultimately, we discuss EBI2 as a possible target for therapeutic intervention.

Oxysterols as EBI2 agonists

Using different approaches, two groups simultaneously identified 7α,25-OHC and closely related oxysterols as natural ligands for EBI2 [6, 7] (Fig. 1). Hannedouche et al. [6] used classical biochemistry to purify endogenous agonists from septic sheep liver tissue that was able to activate EBI2. Subsequent mass spectrometry allowed for prediction of a candidate mass, which was identified as dihydroxylated cholesterol using a chemical library. Liu et al. [7] used rat- and porcine-spleen tissue as starting material. The natural EBI2 ligand 7α-hydroxycholesterol was detected by gas chromatography, and this finding prompted further testing of about 30 oxysterols for EBI2-binding capacity, which led to the characterization of 7α,25-dihydroxycholesterol (7α,25-OHC), 7α,27-OHC and 7β,25-OHC as the most potent EBI2 agonists [7], as also described by Hannedouche et al. [6] (Fig. 1). However, it is worth emphasizing that these studies not only identified these three potent agonists, but rather a family of signaling molecules with specific structural characteristics as ligands for EBI2, i.e. the oxysterols.

Oxysterols are oxidized derivatives of cholesterol and have been linked to several physiological processes such as sterol and fat metabolism, bile acid synthesis, and lipid transport. Notably, control of cholesterol biosynthesis by sterol regulatory element-binding protein has been shown to be regulated by oxysterols. This is mediated by oxysterol binding to the insulin-induced gene 1 (INSIG1) with a subsequent block of sterol regulatory element-binding protein-mediated gene transcription, which coordinates cholesterol biosynthesis [15, 16]. Nuclear hormone receptors such as the liver X receptors [17] and the two retinoid related orphan receptors ROR-α and ROR-γ [18–20] have long been recognized as principal mediators of oxysterol signaling, and both types of receptors have been implicated in inflammation and immune regulation. Whereas liver X receptors and their ligands are negative regulators of macrophage inflammatory gene expression [21] and constitute a metabolic checkpoint for immune-cell proliferation [22], ROR-γ is the key transcription factor to orchestrate differentiation of pro-inflammatory T helper 17 cells [23]. In addition to the nuclear hormone receptors, it was shown in 2007 that the
7TM oncoprotein Smoothened can be activated by oxysterols [24]. Subsequent studies showed that 20(S)-hydroxycholesterol is most potent and interacts with the cysteine-rich extracellular domain of smoothened [25, 26].

Structural and functional properties of EBI2

EBI2 is evolutionarily conserved but does not have any close structural homologs, as the most related receptor (GPR17) is only 31% identical to EBI2 [27]. By exploiting the intrinsic activity observed upon heterologous expression of EBI2 in HEK293 cells, Rosenkilde et al. showed selective receptor signaling through the Gαi-mediated signaling pathway several years before its deorphanization [1]. Subsequent to this, oxysterol-induced activation of EBI2 was demonstrated to involve several others of the classical 7TM downstream effects including mobilization of intracellular calcium, activation of MAP kinases, and cell proliferation, most of which were pertussis toxin-dependent indicating the involvement of Gαi-mediated signaling [6, 8, 9]. Also, G protein-independent activation via β-arrestin recruitment has been described for EBI2 [6, 7, 9]. The most potent oxysterol ligand for EBI2, 7a,25-OHC, displays potencies ranging from 200 nM in β-arrestin recruitment to 0.1 nM in GTPγS binding and, thus, seems to be biased toward G protein-mediated signaling pathways (Table 1). 7a,25-OHC contains three hydroxyl groups attached to its steroid backbone at positions 3, 7, and 25 (Fig. 1). Structure–activity relationship studies revealed that the potency of EBI2 activation by oxysterols. For instance, subtle changes as altering the conformation of the 7-OH group from alpha to the beta position results in an up to 50-fold decrease in potency as determined by EBI2-induced migration [6]. Moreover, removing one of the hydroxyl groups causes even larger decreases in potency [6, 7], indicating that a defined set of anchor residues is present in EBI2.

Using site-directed mutagenesis, two groups identified a selection of residues in the binding pocket of EBI2 that are of importance for oxysterol binding [28, 29]. Residues common to both studies included an arginine at the top of transmembrane region 2 (TM-2) (Arg87 in position II:20/2.60 – the positions are given according to the numbering system suggested by Schwartz [30] followed by the Ballesteros system [31], separated by a slash), two tyrosines in TM-3 (Tyr112 and Tyr116 in positions III:9/3.33 and III:13/3.37, respectively) and a tyrosine in TM-6 (Tyr260 in position VI:16/6.51) (Fig. 2B). Substitution of any of these residues with alanine dramatically decreased 7a,25-OHC binding to EBI2. Conservative substitutions revealed that Arg87, Tyr116, and Tyr260 might interact with the oxysterol via hydrogen bonds, whereas Tyr112 binds to the agonist through an aromatic interaction (Fig. 2C and D). Moreover, an asparagine (Asn114, III:11/3.35) that is situated between Tyr112 and Tyr116 in TM-3 was also suggested to be highly important for 7a,25-OHC binding to EBI2 [29]. Both studies used in silico ligand docking to examine the putative binding mode of 7a,25-OHC in an EBI2-homology model that was based on the crystal structure of CXC chemokine receptor 4 (CXCR4) [32]. Interestingly, the binding modes differ substantially in these two studies. Thus, using ROSETTA simulation, Benned-Jensen et al. found that the lowest energy binding mode of 7a,25-OHC is in a horizontal orientation with the three 7a,25-OHC hydroxyl groups interacting with Arg87, Tyr116, and Y260 [28]. Conversely, in the study by Zhang and colleagues [29], the oxysterol is oriented vertically and interacts primarily with Asn114, Arg87, and a glutamate (Glu183) in the extracellular loop 2 ECL2. In both cases, the dockings were subject to bias as our ROSETTA simulation was restricted to a sphere covering the binding pocket only and that of Zhang and colleagues was done manually. In any case, the two studies firmly establish that a collection of residues facing the main binding pocket of EBI2 are crucial to 7a,25-OHC binding of which Arg87, Asn114, Tyr116, and Tyr260 are of particular importance (Fig. 2B and D). Despite these detailed descriptions of putative oxysterol-binding modes in EBI2, it is still not known how the ligand enters the receptor. Given its lipid nature, it is tempting to suggest that oxysterols access the binding pocket laterally after first associating with the lipid membrane, as recently described for S1P (sphingosine 1-phosphate) access to its cognate 7TM receptor [33]. That being said, only an oxysterol-bound EBI2 crystal structure will provide clarity for this interesting question.

The first small molecule inhibitor of EBI2, GSK682753A, was described by Benned-Jensen et al. [8] at the same time as the endogenous ligands. This piperidine-based antagonist was found by high-throughput screening of a nonpeptide library inhibiting the activity of an overexpressed recombinant EBI2 receptor in melonophores [8]. GSK682753A and structurally related compounds inhibit β-arrestin- and G protein-mediated signaling with nM potency (Table 1). It functions as a competitive antagonist and, in accordance with this, initial mutational analyses have shown that it binds to EBI2 in the same region as 7a,25-OHC [9]. Importantly, it also inhibits oxysterol-induced cell migration and EBI2-induced cell proliferation [8, 9] and thus establishes a clinical relevance of EBI2 antagonists in various inflammatory diseases and in EBV-mediated cancers, where EBI2 may be involved (see below).

Roles of the oxysterol–EBI2 pathway in immune regulation

Cholesterol and its downstream metabolites, oxysterols, have multiple effects on the innate and adaptive immune system (for a recent review see [34]). However, here we solely focus on the oxysterol–EBI2 axis in immunity. Based on the dynamic expression pattern of EBI2 in B cells, it was earlier hypothesized that EBI2 regulates B-cell migration [10, 11]. Today, these assumptions have changed into an established understanding of how up- and downregulation of EBI2 and its oxysterol ligand and of certain chemokine receptors (CXC5, CCR7, and CXCR4) act together in the fine-tuned control of B-cell localization during antibody responses (for a recent review, see [35]). EBI2 is upregulated during B-cell maturation and is highly expressed in mature
B cells, also known as naïve B cells. However, it is sharply downregulated by the transcriptional repressor B-cell lymphoma-6 in GC B cells, which undergo somatic hypermutation and proliferation [36]. Identification of the endogenous EBI2 ligands led to the finding that oxysterols act as chemoattractants for immune cells expressing EBI2 in vitro and in vivo [6, 7]. Extending the initial studies on EBI2-ligand identification, it was demonstrated that the enzymes that are required for formation of 7α,25-OHC (HSD3B7) act in concert to form a gradient necessary for appropriate positioning of B cells in the GC [37].

Whereas EBI2-dependent migration of dendritic cells (DCs) had already been demonstrated at the time of EBI2 ligand identification [6], two recent studies developed a more detailed picture as to the functional role of the oxysterol–EBI2 chemoattractant system in DCs [38, 39]. The main function of DCs is to survey the body for blood-born antigens, which, once detected, are transported by DCs to the spleen or secondary lymphoid organs and presented to lymphocytes to promote T-cell and antibody responses. The oxysterol–EBI2 pathway has been shown to position CD4+ DCs in the marginal zone of the bridging channels [38]. Genetic inactivation of the EBI2 or CH25H, the key enzyme for ligand production, greatly reduces the CD4+ DC population in this area leading to defects of T-cell activation and drastic reduction in antibodies IgM and IgG1 [39]. In addition to DC migration, EBI2 was recently shown to be a negative regulator of IFN responses in plasmacytoid DCs and myeloid cells, a function proposed to reduce autoimmunity by balancing IFN responses to foreign and to self-nucleic acids [40].

In addition to adaptive immune cells, innate immune cells, such as monocytes and macrophages also express EBI2, but the role of EBI2 signaling in these cells warrants exploration [1, 41]. Recent studies by Eibinger et al. [42] showed that the monoblastic leukemia cell line THP-1 displays EBI2-dependent migration toward synthetic 25-OHC, or toward oxysterol secreted from tumor-associated monocytes and macrophages toward brain tumors possibly modulates gliomagenesis. Moreover, Nau et al. investigated time-course dependent changes in the macrophage transcriptome after stimulation with various bacterial pathogens. Of note, macrophage stimulation with Salmonella strains induced up to 20-fold increases in EBI2 mRNA levels [43]. Although the role of EBI2 in macrophages is still under investigation, there are several reports showing a crucial role for macrophages in oxysterol production. Treatment of macrophages with LPS, which is a ligand of Toll-like receptor 4, or with type 1 interferon greatly increases

### Table 1. Potencies of the EBI2 agonist 7α,25-OHC and the EBI2 antagonist GSK682753A.

| Functional readout | 7α,25-OHC-induced activation | GSK682753A-induced inhibition |
|--------------------|-------------------------------|-------------------------------|
|                     | EC50 (nM)                     | IC50 (nM)                     |
| **Cellular system** |                               |                               |
| Gαi coupling        | SK-N-MC cells                 | HEK293 cells                  |
|                    | 2                             | 54                            |
| ERK1/2 MAPK activation | CHO cells                  | CHO cells                     |
|                    | 3,0                           | 8,0 to 76                     |
| p38 MAPK activation | CHO cells                     | HEK293 cells                  |
|                    | ND                            | 2,6                           |
| GTPγS binding      | COS7 cells                    | HEK293 cells                  |
| calcium release     | CHO-Kβ-arrestin cell line     | CHO cells                     |
| β-arrestin recruitment | HEK293 cells                  | 40                            |
| Cell migration      | hEBI2-overexpressing mouse B cells | 0,007                        |
|                    | ~10                           | ND                            |
| Cell proliferation  | Impact of 7α,25-OHC on B cells | No effect                    |
|                    | LPS-induced proliferation     | B lymphocytes from wt         |
|                    | 1100                          | 1300 (mEBI2)                  |
|                    | Human B cells                 | over-expressing mice          |
|                    | Human B cells                 | 3000 (hEBI2)                  |
|                    | Burkitts lymphoma pre-B-cell RS11846 | 1100                        |

7α,25-OHC: 7α,25-dihydroxycholesterol; EC50: half maximal effective concentration; IC50: half minimal inhibitory concentration; ERK1/2: extracellular–signal-regulated MAP kinases 1/2; GTPγS: guanosine 5′-O-[gamma-thio]triphosphate; CREB: cAMP response element-binding-protein; EBI2wt: wild type Epstein-Barr virus-induced gene 2; EBI2-0E: overexpressed; hEBI2: human EBI2; HEK293: human embryonic kidney 293; CHO: Chinese hamster ovary; mEBI2: murine EBI2; COS7: CV-1 (simian) in Origin, and carrying the SV40 genetic material; SK-N-MC: human neuroepithelioma cell line; LPS: lipopolysaccaride; ND: not determined.
expression of cholesterol 25-hydroxylase, resulting in a markedly higher level of oxysterol in the blood [44, 45]. This oxysterol production is an important component of the antiviral defense. As such, treatment of cultured cells with 25-OHC in vitro inhibits the growth of a broad spectrum of enveloped viruses, whereas inactivation of Ch25h by gene targeting in mice leads to an increased susceptibility to murine gamma herpes virus 68 (MHV68) [46]. In addition, treatment of humanized mice with 25-OHC protects them from HIV infection [46]. This effect is probably due to multiple mechanisms related with both viral entry and suppression of viral replication [46, 47] and is not dependent on the action of the EBI2 receptor.

The role of EBI2 in EBV infection

Among many virus-regulated endogenous proteins, EBI2 shows the highest expression during both lytic and latent EBV infection [1, 3, 48], which makes this gene particularly interesting in relation to EBV infection. EBV was identified in 1964 as the first human tumorigenic virus, and is the only known human γ-herpesvirus [49, 50]. It establishes lifelong persistence in memory B cells and is widespread in all human populations [49]. EBV primarily infects B cells and epithelial cells and induces a highly proliferative phase during which the virus is spreading (the lytic phase). Following the lytic phase, EBV establishes a persistent infection in B memory cells, which is characterized by latency and recurring virus reactivation [49]. The latent infection has been proposed to occur by direct infection of GC cells or memory B cells [51] or by EBV mimicking of the antigen-driven maturation of naïve B cells into memory B cells [52] (See Fig. 3 for a summary of the antigen-driven and EBV-mediated B-cell differentiation and the role of EBI2 in these processes). B cells undergo differentiation via GC development and affinity maturation during antigen-driven B-cell maturation. By inducing expression of viral proteins and regulating the expression of host proteins to mimic the immune signals that promote B-cell differentiation, EBV may promote the development of EBV-infected memory B cells. Memory B cells resulting from EBV infection thus have a similar cell-surface phenotype as antigen-induced memory B cells and therefore, escape immune surveillance [52]. The GC provides a necessary environment for the development of EBV-infected naïve B cells into memory cells, but it is also a hostile environment for the infected B cells. EBV-infected B cells in patients with infectious mononucleosis tend to avoid the GCs and accumulate in extrafollicular regions [53]. Although the role of EBI2 during both lytic and latent EBV infection remains unclear, has been suggested that upregulation of EBI2 by EBV ensures the migration of infected B cells toward the extrafollicular regions and promotes the survival of these cells during lytic infection [10]. In this way, the spreading of virus will not suffer from apoptosis of infected cells.

Our own recent studies on mice which express human EBI2 under the intronic IgH enhancer in order to ensure B-cell localization have shown that high EBI2 expression in B cells results in B-cell proliferation ex vivo [8]. This suggests that the role of EBI2 in EBV infection is not exclusively related to its migratory effects, but also involves proliferative effects. Such effects might be particularly important during the lytic phase of the EBV...
The role of EBI2 in antigen-driven B cell differentiation and in the lifecycle of EBV. Upon a successful lytic infection, EBV establishes a persistent infection in memory B cells. This has been proposed to be achieved by either direct infection of these cells (not shown in this figure) or by mimicking the antigen-driven B-cell differentiation into memory cells [52]. (A) Antigen-activated naive B cells differentiate into highly proliferating B-cell blasts by the help of T cells. B-cell blasts then enter the follicles, where they expand to form GCs. Within the GCs, activated B cells undergo affinity maturation and proliferation upon antigen recognition on the surface of dendritic cells and stimulation by T cells. Finally, resting memory B cells enter the peripheral circulation. (B) During lytic EBV infection, virus-infected B cells proliferate and ensure virus spreading. Upregulation of EBI2 may ensure avoidance of the hostile environment of the GCs. (C) During latent EBV infection, EBV has been proposed to induce and regulate expression of viral proteins and host proteins to mimic the immune signals that promote B-cell differentiation [52]. The EBI2 expression level is indicated by ++, +, and ? (if unknown).

infection, as it might secure the expansion of EBV-infected B cells. Intriguingly, Liu et al. found that 7α,25-OHC had no impact on LPS-induced B-cell proliferation [7], indicating that the proliferation induced by EBI2 (and inhibited by the EBI2 antagonist GSK682753A [8]) could be independent of 7α,25-OHC.

Despite the discovery of EBI2 as an EBV-upregulated protein 20 years ago, our knowledge on the role of EBI2 in EBV infection is still incomplete. However, the fact that the most well-known EBV protein, latent membrane protein 1 (LMP1), induces EBI2 expression [5], suggests that these two proteins are tightly related. LMP1 is a viral CD40 mimic and is considered as the major EBV oncoprotein, as LMP1 overexpression leads to B-cell transformation both in vitro [54] and in vivo [55]. In vivo studies have shown that CD40 engagement promotes the EBI2-mediated migration of spleen B cells, suggesting that the EBI2-mediated cell positioning is highly important for the EBV infection [12]. Similar to EBI2, LMP1 is expressed during both lytic and latent EBV infection [52]. LMP1 promotes survival and proliferation of infected B cells [52], and thus represents one of many viral proteins with importance for virus survival [49]. The recently shown role of oxysterol–EBI2 signaling in the anti-viral immune response [43, 46] leaves us questioning whether the high induction of EBI2 following EBV infection is indeed mediated by the virus or if it is a host response to the virus. Further studies of the interplay between EBI2 and EBV as well as EBV-encoded proteins could provide insight into the viral exploitation of the host organism and in particular the host immune system and also the immune response to viral diseases.

Targeting the oxysterol–EBI2 pathway for disease treatment

As we are learning more about the physiological and pathological role of the oxysterol–EBI2 pathway, the question about opportunities for targeting this pathway for pharmacological intervention in a disease setting is raised. Several factors that might support a specific disease indication should be considered. Exploring the connection of this pathway to human genetic studies could help to establish a solid link between oxysterol–EBI2 signaling and disease. The other approach would be to investigate expression of the pathway components, such as the receptor and the enzymes involved in the generation and metabolism of specific oxysterols, under disease conditions. Direct measurement of oxysterols in fluids and tissues has been challenging. That being said, especially the methods for detection by mass spectrometry have recently
advanced significantly (for a recent review see [56]). In our view, a combination of all three avenues (human genetics, expression analysis, and oxysterol measurements) will be needed to define a disease indication in which modulation of this pathway would be most beneficial. What is the best intervention point within the oxysterol–EBI2 pathway to have beneficial effects? Is it receptor blockade or activation, or rather modulation of oxysterol production or action? The recent results demonstrating an increased susceptibility of CH25H knockout mice to viral infection have pointed toward an interesting potential of oxysterols and CH25H antagonists as possible therapeutics in viral infections [46, 47]. Notably, inactivation of CH25H has also been shown to increase IgA levels [57].

A pathological role of the oxysterol–EBI2 pathway is particularly compelling in diseases involving an immune system dysregulation, or diseases involving EBV infection. Many of these diseases overlap, as, in addition to EBI2, EBV regulates many different proteins related to the immune system, such as chemokines and their receptors [48]. There are many disorders in which immune dysregulation have been implicated. First and foremost, autoimmune and autoinflammatory disorders, such as type-1-diabetes (T1D), multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, have been connected to an aberrant activation of the immune system [58–61]. For each of these diseases, different components of the immune system have been implicated. For T1D it is interesting to note that a genetic link of EBI2 and T1D with EBI2 controlling an IRF7-driven inflammatory network (IDIN) has been reported. The authors combined analyses of gene expression data and DNA sequence variations to delineate first the IDIN. Subsequently, they mapped the control of this IDIN to the chromosomal locus (rat and human) which encodes the EBI2 receptor [62].

Inflammation substantially contributes to the pathophysiology of cardiovascular disease, and especially of atherosclerosis [63]. As high levels of oxysterols are present in an atherosclerotic plaque [64] and EBI2 is expressed on monocytes [1, 41], which have a central role in atherosclerosis [65], it is tempting to speculate that the oxysterol–EBI2 pathway is involved in the recruitment of immune cells to atherosclerotic lesions. Thus, EBI2 blockade might provide a therapeutic benefit in atherosclerosis.

Almost all currently known effects of the oxysterol–EBI2 pathway have been associated with the chemotactic properties of oxysterols on EBI2-expressing immune cells. However, as high expression of EBI2 prevents B cells from participating in the GC reaction, EBI2 signaling in B cells might influence the kinetics between an immediate versus a long-term antibody response, one can also speculate that an increase in the number of B cells that undergo somatic hypermutation and proliferation in the GCs might lead to a more vigorous immune response and/or to the selection of B cells that produce antibodies with increased avidity to the challenging antigen. Rigorous experimental testing will be needed to verify this hypothesis.

In summary, the identification of oxysterols as natural ligands for EBI2 has demonstrated an unanticipated link between EBI2 and the mechanisms through which oxysterols shape the innate and adaptive immune responses, thereby establishing a new physiological dimension for oxysterols as biological messengers. Further exploration to establish a solid link between the oxysterol–EBI2 pathway and pathophysiology of human disease is eagerly awaited.

Acknowledgements: The authors V. Daugvilaite, K.N. Arfelt, T. Benned-Jensen, and M.M. Rosenkilde are supported by grants from the Danish Council for Independent Research | Medical Sciences, the Lundbeck Foundation, the Novo Nordisk Foundation, the AP Moller Foundation, and the Aase and Einar Danielsen Foundation.

Conflict of interest: A.W. Sailer is an employee of Novartis Pharma AG and does hold stock and stock options in this company. All other authors declare no financial or commercial conflict of interest.

References

1 Rosenkilde, M. M., Benned-Jensen, T., Andersen, H., Holst, P. J., Kledal, T. N., Luttichau, H. R., Larsen, J. K. et al., Molecular pharmacological phenotyping of EBI2. An orphan seven-transmembrane receptor with constitutive activity. J. Biol. Chem. 2006. 281: 13199–13208.
139 Kuppers, R., Rooyackers, O., et al., The role of IRF7-driven expression of Epstein-Barr Virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders. Diagn. Mol. Pathol. 2007: 158–168.

140 Capello, D., Rossi, D. and Gaidano, G., Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol. Oncol. 2005: 61–67.

Abbreviations: EBV: Epstein-Barr virus · EB2: Epstein-Barr virus-induced molecule 2/Epstein-Barr Virus upregulated gene 2 · IRF7: interferon regulatory factor 7 · LMP1: latent membrane protein 1 · TID: type-1-diabetes · 7a,25-dihydroxycholesterol

Full correspondence: Dr. Mette M. Rosenkilde, Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark
Fax: +45-35327610
e-mail: rosenkilde@sund.ku.dk

Additional correspondence: Dr. Andreas Sailer, Developmental & Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland

© 2014 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.eji-journal.eu